Angus M. McLean

SLI381 (Adderall XR), a Two‐Component, Extended‐Release Formulation of Mixed Amphetamine Salts: Bioavailability of Three Test Formulations and Comparison of Fasted, Fed, and Sprinkled Administration

Simon Tulloch, Yuxin Zhang, Angus M. McLean et al. · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · 2002 · 57 citations

Pharmacy, Pharmaceutics, Pharmacology +17

Pharmacokinetic Evaluation of Twice‐Daily Extended‐Release Carbamazepine (CBZ) and Four‐Times‐Daily Immediate‐Release CBZ in Patients with Epilepsy

William R. Garnett, Benjamin Levy, Angus M. McLean et al. · Epilepsia · 1998 · 42 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +13

The influence of plasma butyrylcholinesterase concentration on thein vitro hydrolysis of cocaine in human plasma

Susan P. Browne, Elizabeth Slaughter, Richard A. Couch et al. · Biopharmaceutics & Drug Disposition · 1998 · 29 citations

Medicine, Biochemistry, Pharmacology +15

The Influence of Food on the Bioavailability of a Twice‐Daily Controlled Release Carbamazepine Formulation

Angus M. McLean, Susan Browne, Yuxin Zhang et al. · The Journal of Clinical Pharmacology · 2001 · 29 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

Single-Dose Pharmacokinetics of HLD200, a Delayed-Release and Extended-Release Methylphenidate Formulation, in Healthy Adults and in Adolescents and Children with Attention-Deficit/Hyperactivity Disorder

Ann Childress, Shailly Mehrotra, Jogarao Gobburu et al. · Journal of Child and Adolescent Psychopharmacology · 2017 · 28 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17